Table 1.
Mean values (±SD) of parameters at the basal evaluation and after the six-month treatment
| Pravastatin (n = 20) | Ezetimibe + Fenofibrate (n = 21) | ANOVA | ||||
|---|---|---|---|---|---|---|
|
|
||||||
| Basal | 6-month | Basal | 6-month | Time | Treatment | |
| BMI, kg/m2 | 25.4±3.1 | 25.2±3.6 | 24.9±3.1 | 25.1±2.8 | 0.64 | 0.72 |
| Total cholesterol, mg/dl | 248±39 | 224±43* | 241±34 | 199±35*,° | 0.007 | 0.012 |
| HDL cholesterol, mg/dl | 47±11 | 46±9 | 44±10 | 53±12*,° | 0.41 | 0.008 |
| LDL cholesterol, mg/dl | 149±32 | 125±36* | 149±33 | 122±37* | 0.005 | 0.59 |
| Non-HDL cholesterol, mg/dl | 200±35 | 178±38* | 196±36 | 147±32*,° | 0.005 | 0.011 |
| Triglycerides, mg/dl | 263±96 | 248±89 | 265±118 | 149±37*,° | 0.38 | <0.001 |
| Creatinine, mg/dl | 0.86±0.12 | 0.88±0.14 | 0.89±0.16 | 0.85±0.14 | 0.52 | 0.47 |
| Fasting glucose, mg/dl | 83±12 | 85±14 | 87±12 | 84±9 | 0.61 | 0.58 |
| HOMA index | 3.9±2.6 | 4.2±3.2 | 4.1±2.8 | 4.3±3.5 | 0.37 | 0.55 |
| ALT, U/l | 45±37 | 39±28 | 34±22 | 36±20 | 0.49 | 0.51 |
| AST, U/l | 44±38 | 39±34 | 41±29 | 37±25 | 0.53 | 0.46 |
| CK, U/l | 159±116 | 158±119 | 186±125 | 190±128 | 0.72 | 0.43 |
| hsCRP, mg/L | 3.13±3.25 | 2.44±1.40 | 2.88±3.02 | 2.41±1.29 | 0.23 | 0.52 |
| CD4+ count, n/mm3 | 598±238 | 582±241 | 605±320 | 592±285 | 0.61 | 0.73 |
BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA: homeostasis model assessment; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CK: creatine kinase; hsCRP: high-sensitivity C-reactive protein; ns: non-significant.
ANOVA Time: basal versus 6 months, Treatment: ezetimibe + fenofibrate vs. pravastatin.
*
0.02 < p<0.001 6-month vs. basal evaluation.
°
0.05 < p<0.001 ezetimibe + fenofibrate vs pravastatin at 6-month.